Skip to Main Content

++

RREVIEW OF SECOND-GENERATION/NEWER AGENTS

++

PLACE IN THERAPY

++

The advent of the second-generation antiepileptic drugs ushered in a period of improved management of patients with epilepsy. The introduction of these agents began in 1993 and greatly expanded the available epilepsy treatment options. Currently, 11 second-generation antiepileptic drugs (AEDs) are approved for use in the United States. Table 4-1 provides a summary of the available second-generation AEDs. Due to the regulations of the Food and Drug Administration (FDA) with respect to studying AEDs in the United States, many of these agents are initially approved as adjunctive agents. In essence, they are added to an established therapeutic regimen of patients being managed primarily with a first-generation AED (i.e., carbamazepine, phenobarbital, phenytoin, or valproic acid). Most of them are approved for use as adjunctive therapy in the management of partial seizures with or without secondary generalization, primary generalized tonic-clonic seizures, or myoclonic seizures. As more data emerge, monotherapy approval for these agents may be pursued and the use of these agents will inevitably be expanded in clinical practice. At times, these agents may also be used for nonepileptic purposes. For example, gabapentin and pregabalin, while initially used for seizure management, are used almost exclusively today for the management of neuropathic pain and other pain syndromes.

++
Table Graphic Jump Location
TABLE 4-1Summary of Second-Generation Antiepileptic Drugs

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessPharmacy Full Site: One-Year Subscription

Connect to the full suite of AccessPharmacy content and resources including 30+ textbooks such as Pharmacotherapy: A Pathophysiologic Approach and Goodman & Gilman's The Pharmacological Basis of Therapeutics, high-quality videos, images, and animations, interactive board review, drug and herb/supplements databases, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessPharmacy

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.